. Author manuscript; available in PMC: 2019 Jun 13.

Published in final edited form as: Int J Tuberc Lung Dis. 2017 Jan 13;21(3):286–296. doi: 10.5588/ijtld.16.0469

Table A.2.

Completion of follow-up status by completion of treatment in the North American region (n = 6318)

	Did not complete treatment (n = 1481)		Completed treatment (n = 4837)
	Did not complete follow-up^* (n = 385)	Completed follow-up (n = 1096)	Did not complete follow-up^* (n = 386)	Completed follow-up (n = 4451)
Regimen	n (%)	n (%)	n (%)	n (%)
3HP-DOT (n = 3254)^†	141 (36.6)	450 (41.1)	222 (57.5)	2441 (54.8)
9H-SAT (n = 3064)^†	244 (63.4)	646 (58.9)	164 (42.5)	2010 (45.2)
Total (n = 6318)	385 (26.0)^‡	1096 (74.0)^‡	386 (8.0)^§	4451 (92.0)^§

Participants had the opportunity to continue study follow-up after completion or discontinuation of treatment; non-completion of follow-up = (385 + 386)/6318 = 12.2%. The difference in the proportion of non-completion of follow-up between those who did not complete treatment (385/1481, 26.0%) vs. those who completed treatment (386/4837, 7.7%) was statistically significant (P < 0.001).

^†

3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily self-administered INH (maximum dose, 300 mg).

^‡

The denominator for the percentage is all participants who did not complete treatment (n = 1481).

^§

The denominator for the percentage is all participants who completed treatment (n = 4837).

H, INH = isoniazid; P, RPT = rifapentine; DOT = directly observed therapy; SAT = self-administered treatment.